| Background and Objective:Colorectal cancer (CRC) is the third most common malignant neoplasm worldwide. Traditional theories suggest that tumor growth occurs when all tumor cells work together and result in proliferation, so treatment has been mainly directed against the majority of the cells in tumor tissue, which often relapse, metastasize, and lead to treatment failure. Major burdens in the treatment of Colorectal cancer are the high percentage of recurrence and resistance to chemotherapy. The recent identification of "side population" cells in a number of unrelated human cancers and their normal tissue sources has renewed interest in the hypothesis that cancers may arise from somatic stem/progenitor cells. These cancer stem cells provide a reservoir of cells that can self-renew, maintain the tumor by generating differentiated non-stem cells which make up the bulk of the tumor and are responsable for recurrence after ablative surgery and chemoradiotherapy. As cancer stem cells have been successfully isolated from different tumor tissues, in-depth study of their function in relation to traditional cancer treatment faces enormous challenges. At the same time, a new theoretical basis has been provided for the in-depth study of tumorigenesis and the evaluation of prognosis of cancer therapy. Also, new ideas have been introduced for cancer therapy. Therefore, radical treatment of cancer can be achieved through killing cancer stem cells.Phenotypic characterization of colorectal Cancer Stem Cell is still debated although putative Cancer Stem Cell populations have been identified in several solid tumors based on functional stem cell-like properties and expression of specific markers. Recently, CD133. CD166 and CD44 such markers have been proposed for colorectal cancer. However, there is no immunohistochemical study on the expression of Cancer Stem Cell markers CD 133,CD 166 and CD44 in Colorectal Cancer. We detection the immunohistochemical expression of CD 133,CD166 and CD44 in colorectal carcinoma,adjacent and normal mucosal tissues, to evaluate the expression of their different characteristics and clinical significance.Methods:Expression of CD 133. CD 166 and CD44 in 23 cases of colorectal carcinoma,adjacent and normal mucosal tissues detected using immunohistochemical MaxVisionTM method. Their different expression and association with clinicopathologieal parameters were also analyzed.Results:CD133 were expressed in 47.8%,17.4%, and 0 cases of colorectal carcinoma. adjacent and normal mucosal tissues, the expression significantly associated with colorectal cancer (P<0.01). CD166 were expressed in 95.6%,78.3%, and 73.9%cases and CD44 were expressed in all 100% cases of colorectal carcinoma,adjacent and normal mucosal tissues; there expression no significant associated with colorectal cancer (P> 0.05). CD 133 were high expressed in 39.1%,0, and 0 cases of colorectal carcinoma,adjacent and normal mucosal tissues, the high expression significantly associated with colorectal cancer (P<0.01). CD166 were high expressed in 39.1%,8.7%, and 4.3%cases of colorectal carcinoma,adjacent and normal mucosal tissues, the high expression significantly associated with colorectal cancer (P<0.01),CD44 were high expressed in 52.2%, 4.3%, and 0 cases of colorectal carcinoma,adjacent and normal mucosal tissues, the high expression significantly associated with colorectal cancer (P<0.01). No significant association of their high expression in cancer tissues with age, gender, tumor size, depth of invasion, differentiation, Dukes stage, lymph node metastasis, distant metastasis and preoperative treatment of CRC was found (P> 0.05).Conclusion:1. The high expression in CRC tissues of CD 133, CD166 and CD44 is up-regulated, and there high expression in CRC tissues are not associated with clinicopathological parameters.2,The overexpression of CD 133 in CRC tissues is a distinctive feature.3,The expression rate,scope and number of CD 133+cells are less than CD 166+or CD44+cells. The expression of CD 133+cells is more chemotaxis to tumors and the expression of CD133+cells in the tumor glands in the more centralized. The expression of CD133+cells have higher characteristic. |
PDF Full Text Request